tradingkey.logo

Harrow Inc

HROW
View Detailed Chart
37.480USD
-3.090-7.62%
Close 10/10, 16:00ETQuotes delayed by 15 min
1.38BMarket Cap
LossP/E TTM

Harrow Inc

37.480
-3.090-7.62%
Intraday
1m
30m
1h
D
W
M
D

Today

-7.62%

5 Days

-17.50%

1 Month

-4.92%

6 Months

+55.58%

Year to Date

+11.71%

1 Year

-26.09%

View Detailed Chart

TradingKey Stock Score of Harrow Inc

Currency: USD Updated: 2025-10-10

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Harrow Inc's Score

Industry at a Glance

Industry Ranking
56 / 173
Overall Ranking
149 / 4697
Industry
Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 8 analysts
Buy
Current Rating
67.914
Target Price
+81.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Harrow Inc Highlights

StrengthsRisks
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 125.31% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 24.10.
Undervalued
The company’s latest PE is -134.46, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 21.34M shares, decreasing 15.40% quarter-over-quarter.
Held by Private Capital
Star Investor Private Capital holds 1.95M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.25.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Harrow Inc Info

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Ticker SymbolHROW
CompanyHarrow Inc
CEOMr. John P. Saharek
Websitehttps://www.harrow.com/
KeyAI